The firm is betting on pairing KTX-1001 with BMS's mezigdomide and Onyx's Pomalyst in a crowded, competitive field.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback